VivoSeq
0

Pipeline Programs

6

Active Trials

1

Companies Involved

HCC is an early-stage landscape with 0 programs across 1 company. The most active players are Bayer.

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

25/100

Attrition Rate

19/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

16

clinical trials

Unknown status6 · 38%
Recruiting6 · 38%
Terminated2 · 13%
Withdrawn1 · 6%
Completed1 · 6%

Trial Activity

16 trials

IIT2025-03-YANG-LIFT-HCC
Recruiting··Phase 2·NCT07489976·41 enrolled
FGF19 Overexpression Combination Unified Study in HCC-19
Recruiting·RRenJi Hospital·Phase 2·NCT06978933·42 enrolled
Optimization for Regorafenib in HCC
Terminated·SSC Liver Research Consortium, LLC·Phase 2·NCT04476329·7 enrolled
A Study of PTS100 in Primary HCC Patients
Unknown status·GGongwin Biopharm Co., Ltd.·Phase 2·NCT03447951·33 enrolled
HR Combined With FOLFOX4 for HCC With PVTT
Unknown status·SSun Yat-sen University·Phase 2·NCT02452853·51 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)